Scarica l'app Stockscreener
164.11
3.21%
-5.44
Dopo l'orario di chiusura:
164.03
-0.08
-0.05%
Precedente Chiudi:
$169.55
Aprire:
$170
Volume 24 ore:
109.69K
Relative Volume:
0.51
Capitalizzazione di mercato:
$6.46B
Reddito:
-
Utile/perdita netta:
$-77.61M
Rapporto P/E:
-71.42
EPS:
-2.2979
Flusso di cassa netto:
-
1 W Prestazione:
-5.30%
1M Prestazione:
-6.36%
6M Prestazione:
+136.20%
1 anno Prestazione:
+136.18%
Intervallo 1D:
$162.89
$172.71
Intervallo di 1 settimana:
$162.89
$181.99
Portata 52W:
$49.00
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Nome
Belite Bio Inc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare BLTE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
164.11 | 6.46B | 0 | -77.61M | 0 | -2.2979 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-26 | Iniziato | BofA Securities | Buy |
| 2026-01-06 | Iniziato | Morgan Stanley | Overweight |
| 2025-12-02 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-11-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-11-20 | Iniziato | Mizuho | Neutral |
| 2023-12-14 | Iniziato | Maxim Group | Buy |
| 2023-07-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Iniziato | SVB Securities | Outperform |
| 2022-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-01 | Iniziato | The Benchmark Company | Buy |
Mostra tutto
Belite Bio Inc Adr Borsa (BLTE) Ultime notizie
Mizuho reiterates Belite Bio stock rating on NDA timeline update By Investing.com - Investing.com Nigeria
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
H.C. Wainwright raises Belite Bio stock price target on NDA timeline - Investing.com Nigeria
Belite Bio Eyes 2027 Launch After Pivotal Win - TipRanks
Belite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at Conference - MarketBeat
The Bull Case For Belite Bio (BLTE) Could Change Following Steeply Wider 2025 Net Losses – Learn Why - Sahm
Belite Bio (BLTE) to Release Earnings on Monday - MarketBeat
What is HC Wainwright’s Forecast for Belite Bio Q1 Earnings? - Defense World
(BLTE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Q1 Earnings Forecast for Belite Bio Issued By HC Wainwright - MarketBeat
Mizuho reiterates Belite Bio stock rating on NDA timeline update - Investing.com
Belite Bio Q4 Earnings Call Highlights - Defense World
Belite Bio (NASDAQ:BLTE) Given New $266.00 Price Target at Cantor Fitzgerald - Defense World
Belite Bio (NASDAQ:BLTE) Price Target Raised to $200.00 at HC Wainwright - MarketBeat
Belite Bio (BLTE) Q4 2025 Earnings Call Transcript - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Price Target Raised to $201.00 - MarketBeat
Belite Bio stock price target raised to $217 by Benchmark on trial data - Investing.com
Belite Bio (NASDAQ:BLTE) Price Target Raised to $266.00 at Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald raises Belite Bio stock price target on pricing outlook - Investing.com
Earnings call transcript: Belite Bio beats Q4 2025 EPS expectations, stock dips slightly - Investing.com
Belite Bio (NASDAQ:BLTE) Shares Down 8.6%What's Next? - MarketBeat
Belite Bio to Participate in the Leerink Global Healthcare Conference - The Manila Times
Belite Bio Posts 2025 Results as Tinlarebant Nears NDA Filing After Phase 3 Win - TipRanks
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - The Manila Times
Stargardt Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ocugen, Kubota Vision Inc, Nanoscope Therapeutics, RBP4 Pty Ltd, Stargazer Pharma, Belite Bio, Alkeus Pharma - Barchart.com
Exploring Belite Bio's Earnings Expectations - Sahm
Liquidity Mapping Around (BLTE) Price Events - Stock Traders Daily
Belite Bio to Host Webcast on March 2, 2026, to Discuss Preliminary, Unaudited Fourth Quarter ... - Caledonian Record
China Universal Asset Management Co. Ltd. Acquires New Position in Belite Bio, Inc. Sponsored ADR $BLTE - Defense World
Belite Bio (NASDAQ:BLTE) Shares Gap UpStill a Buy? - MarketBeat
Belite Bio, Inc (BLTE) Stock Report: Analyst Ratings Signal Strong Buy with 9.62% Potential Upside - DirectorsTalk Interviews
Darwin Global discloses 8.1% Belite Bio (BLTE) holding in 13G/A - Stock Titan
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Sees Large Growth in Short Interest - Defense World
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Short Interest Up 49.4% in January - MarketBeat
Why (BLTE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Belite Bio, Inc (BLTE) Stock Analysis: Biotechnology Innovator With 4.98% Potential Upside - DirectorsTalk Interviews
Belite Bio (NASDAQ:BLTE) Shares Down 5.2%Here's Why - MarketBeat
Belite Bio (BLTE) Valuation Check After Completing Enrollment In Pivotal DRAGON II Trial - Sahm
Belite Bio stock hits all-time high at 177.28 USD By Investing.com - Investing.com Nigeria
Belite Bio stock hits all-time high at 177.28 USD - Investing.com
Belite Bio (NASDAQ:BLTE) Reaches New 12-Month HighHere's What Happened - MarketBeat
Belite Bio (BLTE) Valuation Check As Phase 3 DRAGON Tinlarebant Data Presentations Approach - Sahm
Understanding Momentum Shifts in (BLTE) - Stock Traders Daily
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO) - markets.businessinsider.com
H.C. Wainwright reiterates Buy rating on Belite Bio stock with $185 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on Belite Bio stock with $185 target - Investing.com Nigeria
Belite Bio's (BLTE) Buy Rating Reiterated at HC Wainwright - MarketBeat
Belite Bio Inc Adr Azioni (BLTE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):